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Systematic Review
Effect of cotrimoxazole prophylaxis on malaria occurrence in
HIV-infected patients on antiretroviral therapy in sub-Saharan
Africa*
R. Kasirye1,2, K. Baisley1, P. Munderi2 and H. Grosskurth1
1 London School of Hygiene and Tropical Medicine, London, UK
2 MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda
Abstract objective To systematically review the evidence on the effect of cotrimoxazole (CTX) on malaria in
HIV-positive individuals on antiretroviral therapy (ART).
methods Web of Science, PubMed and MEDLINE, EMBASE, Global Health and Cochrane Library
databases were searched using terms for malaria, HIV and CTX. Studies meeting the inclusion
criteria were reviewed and assessed for bias and confounding.
results Six studies (in Uganda, Kenya, Malawi, Zambia and Zimbabwe) had relevant data on the
effect of CTX on malaria in patients on ART: four were observational cohort studies (OCS) and two
were randomised controlled trials (RCTs); two were in children and one in women only. Samples
sizes ranged from 265 to 2200 patients. Four studies compared patients on ART and CTX with
patients on ART alone; 2 (RCTs) found a significant increase in smear-positive malaria on ART
alone: (IRR 32.5 CI = 8.6–275.0 and HR 2.2 CI = 1.5–3.3) and 2 (OCS) reported fewer parasitaemia
episodes on CTX and ART (OR 0.85 CI = 0.65–1.11 and 3.6% vs. 2.4% of samples P = 0.14). One
OCS found a 76% (95% CI = 63–84%) vs. 83% (95% CI = 74–89%) reduction in malaria
incidence in children on CTX and ART vs. on CTX only, when both were compared with HIV-
negative children. The other reported a 64% reduction in malaria incidence after adding ART to
CTX (RR = 0.36, 95% CI = 0.18–0.74). The 2 RCTs were unblinded. Only one study reported
adherence to CTX and ART, and only two controlled for baseline CD4 count.
conclusion Few studies have investigated the effect of CTX on malaria in patients on ART. Their
findings suggest that CTX is protective against malaria even among patients on ART.
keywords malaria, cotrimoxazole, HIV, antiretroviral therapy
Introduction
Malaria and HIV infection are important global health
problems, and these diseases have a wide geographical
overlap resulting in frequent co-infection [1–4]. HIV
infection is associated with deterioration of the patient’s
immune system and an increased incidence of opportunis-
tic infections (OI) and of malaria [5–8]. Among HIV-
infected patients, the use of daily prophylaxis with
cotrimoxazole (CTX) reduces mortality and morbidity
from OI [9–15], and it reduces malaria incidence in HIV-
infected patients before [12, 16, 17] and after starting
antiretroviral therapy (ART)[18, 19], and in children
exposed to HIV infection[20].
WHO [21] recommends ART for HIV-infected adults
and adolescents with a CD4 count <500 cells/ll or if a
person has TB, is pregnant, is breastfeeding, HBV
co-infected with severe liver disease or in a sero-discordant
partnership. WHO also recommends CTX prophylaxis for
anybody with a CD4 count <350 cells/ll, or clinical stage
3 and 4 disease and irrespective of CD4 count or clinical
stage in areas of high malaria prevalence and/or severe
bacterial infections [22]. This policy aims to reduce OI
and all-cause mortality. The possible preventive effect on
malaria was not originally part of the rationale for CTX
prophylaxis. Indeed, fears about the possible development
of resistance against antimalarial drugs owing to*freely and fully available at www.tmih.com
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wide-spread CTX use were expressed by some authors
[23–25].
CTX use increases patients’ pill burden and cost of
care and is associated with haematological toxicity and
hypersensitivity skin reactions. However, adverse reac-
tions to CTX are rare (<2 per 100 person-years of CTX
use) and mainly mucocutaneous in nature; they resolve
with drug discontinuation [26–28]. With patients on
ART being able to regain near normal immune function,
some researchers recommend stopping CTX once patients
are stable on ART [29, 30]. However, these recommen-
dations are based on studies in industrialised countries
which have fewer malaria and bacterial infections than
sub-Saharan Africa (SSA). So although HIV-infected
patients on ART in SSA may not need CTX for preven-
tion of OI, they might still benefit from its antimalarial
effect [31]. A Guideline Development Group on Cotrim-
oxazole prophylaxis was convened by WHO in 2013.
This group recommended that in settings with high
malaria prevalence and/or severe bacterial infections,
even among patients that are stable on ART, CTX should
be continued [22].
Our objectives were (i) to systematically review
publications on the effect of CTX on malaria in
HIV-infected patients on ART in order to assist policy-
makers in SSA in taking informed decisions within the
context of the epidemiological situation in their area
and (ii) to provide background information for an
ongoing controlled trial of malaria incidence among
HIV-infected patients on ART with and without CTX
co-medication.
Methods
Search strategy
The following databases were searched for publications
to 14 April 2014: EMBASE, PubMed and MEDLINE,
Web of Science, Global Health and the Cochrane
Library. The search used terms for malaria, HIV and
CTX, without a term for ART, to reduce the chance of
missing relevant papers.
A combination of the following MESH terms and free
text was used:
• malaria, malaria incidence, malaria prevalence,
malaria severity, malaria outcomes, malaria treat-
ment, Plasmodium and parasitaemia for malaria.
• cotrimoxazole, trimethoprim/sulfamethoxazole,
septrin and bactrim for cotrimoxazole.
• HIV, human immunodeficiency virus, acquired
immunodeficiency syndrome, AIDS and immune
suppression for HIV infection.
An example of the search strategy as used in MEDLINE
• malaria OR malaria adj3 (occurrence OR incidence
OR prevalence OR treatment OR parasit?emia OR
outcomes OR sever*) OR Plasmodium.
• HIV OR human immunodeficiency virus OR
acquired immunodeficiency syndrome OR AIDS OR
Immune suppres*.
• 1 AND 2.
• cotrimoxazole OR trimethoprim sulfamethoxazole
OR septrin OR bactrim.
• 3 AND 4.
The search results were exported to Endnote reference
management software (Thomson Reuters, version 97)
and duplicates were removed. All titles and abstracts
were screened independently by two authors (RK and
KB); inconsistencies were discussed and consensus on
potential eligibility reached. Abstracts were checked for
studies reporting on a combination of malaria, HIV, co-
trimoxazole and antiretroviral therapy. Review articles
were excluded but their reference lists were checked for
possible additional relevant papers. Reference lists from
papers identified from the systematic search were also
checked. Full text copies of potentially relevant papers
were then obtained. Data requests were sent to authors
of studies for which relevant information might have
been collected but not reported in their publications.
Guidelines on preferred reporting items for systematic
reviews and meta-analyses (PRIMSA) were used.
Included studies
We included studies containing original data on the effect
of CTX on malaria in HIV-infected patients on ART. No
restrictions on area of the world, participant age, lan-
guage or the date of publication were used.
Data extraction
Data from papers identified by the search were indepen-
dently extracted by two authors (RK and KB) using a
standard form to collect the following information: first
author’s name, year of publication, type of study, study
population, study aim, sample size, follow-up time, study
results, how malaria diagnosis was made, number and
severity of malaria episodes and the association between
malaria and CTX.
Bias
Assessment of bias and confounding within studies and
quality of papers was based on PRISMA guidelines[32]
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and the Newcastle-Ottawa quality assessment of studies
scale[33]. Studies were assessed on selection bias, adher-
ence to CTX, objectivity of malaria diagnosis, cohort
retention, follow-up duration (for assessment of seasonal
variation), adjustment for confounding and outcome
reporting. A formal meta-analysis was not performed
owing to the diversity in study methodologies, compari-
son groups and populations.
Results
A total of 516 abstracts were retrieved, of which 492
were removed because they were duplicates, were not rel-
evant or did not meet the inclusion criteria (Figure 1).
Full text was reviewed for 24 abstracts; only 6 had data
on the effect of CTX on malaria in HIV-infected patients
on ART and were retained for the final qualitative syn-
thesis. 16 potentially eligible studies did not report on the
association of CTX and malaria in patients on ART;
authors of 14 papers were contacted where it was felt
that relevant data might have been collected but not
reported. However, none was able to provide information
relevant to this review so the studies were not included.
All six studies included in the final synthesis were con-
ducted in SSA; no relevant studies were found from
malarious areas in other continents. Of the six studies,
two were randomised controlled trials and four were
observational cohort studies; two studies were conducted
among children only and four among adults (one in
women only) (Table 1). Four studies were conducted in
Uganda only (or the analysis of malaria was restricted to
Ugandan sites); the other two were multisite studies con-
ducted in Kenya, Malawi, Uganda, Zambia or Zimba-
bwe. The diagnosis of malaria was based on a patient
having history of fever and a positive blood slide or rapid
diagnostic test (RDT) (4 studies); clinical features alone
or clinical features and a positive blood slide (1 study);
and a positive blood slide or positive RDT, or detection
6 Studies included in 
qualitative synthesis 
18 Papers excluded 
3-Papers covered same population (2 were 
excluded)
16-Papers did not have data on the association  
between CTX and malaria in patients on ART
(even after feedback following request to 
authors)
24 Abstracts subjected to full 
review
244 Abstracts excluded because  
the abstracts did not describe
original data on malaria in HIV  
patients on a combination of CTX  
and ART. 
268 Abstracts reviewed  
248 Duplicates removed 
516 Abstracts identified through database 
searches
Medline (19)
Pubmed (83)
Embase (191)
Global health (49)
Web of science (157)
Cochrane database (17)
Figure 1 Results of the systematic search.
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of Plasmodium falciparum histidine rich protein 2 in
plasma (1 study). Study samples sizes ranged from 265 to
2200 patients. Median length of follow-up was not speci-
fied for one study and was between 4 months and
4.9 years for the others. A summary of studies in the
final synthesis is shown in Table 1.
Summary of study objectives and populations
Bwakura-Dangarembizi et al. [34] conducted a rando-
mised, open-label, controlled trial in Uganda and Zimba-
bwe to assess the effect of stopping vs. continuing CTX
prophylaxis in HIV-infected children and adolescents on
long term ART. The trial enrolled 760 participants with
median age of 7.9 years; at enrolment, the median time
on ART was 2.1 years and median CD4 T-cell percent-
age was 33% (nadir-13%).
Campbell et al. [35] conducted a cluster randomised
(by household) controlled trial in Uganda to investigate
the effect of CTX discontinuation on the incidence of
malaria and diarrhoea among HIV-infected adults on
ART with CD4 > 200 cells/ll. The trial enrolled 836 par-
ticipants; at enrolment, the median time on ART was
3.7 years, median CD4 was 489 (nadir = 129) cells/ll,
and 94% had a viral load <100 copies/ll.
Gasasira et al. [12] assessed the protective efficacy of
CTX on the incidence of falciparum malaria and on the
prevalence of Plasmodium falciparum mutations confer-
ring antifolate resistance among children treated for
malaria in Uganda, comparing HIV-infected children on
daily CTX both on and off ART, and HIV-uninfected
children not taking CTX. The study enrolled 899 chil-
dren (300 HIV infected) with a median age of 7.4 (HIV-
uninfected) and 5.7 years (HIV infected) at enrolment.
The median CD4 T-cell percentage was 23% (HIV-
infected). HIV-infected children contributed 665 person-
years of follow-up, of whom 275 were on ART (292 par-
ticipants).
Mermin et al. [19] assessed the effect of ART on
malaria and the additive effects of CTX, ART and insecti-
cide-treated bed nets (ITNs) in HIV-infected adults attend-
ing clinics of The AIDS Support Organization (TASO) at
two sites in Uganda. Study participants had sequential
exposure to the intervention divided into four phases:
• Phase 1 – no intervention (466 participants; median
CD4 at enrolment = 75 cells/ll)
• Phase 2 – participants started on CTX prophylaxis
(399 participants; median CD4 at enrolment = 77
cells/ll)
• Phase 3 – participants continued CTX and started on
ART (1035 participants; median CD4 at enrol-
ment = 124 cells/ll)
• Phase 4 – participants continued CTX and ART, and
ITNs were provided (985 participants; median CD4
at enrolment = 175 cells/ll)
Skinner et al. [36] assessed the effect of a protease
inhibitor (PI)-based ART regimen on malaria compared
with a nevirapine-based regimen, stratified by CTX use.
Patients were part of the Optimal Combination Therapy
After Nevirapine Exposure study (OCTANE) [37], a mul-
ticentre trial comparing non-nucleoside reverse transcrip-
tase inhibitor (NNRTI) and PI-based regimens for HIV-
infected women with a history of nevirapine prophylaxis
to prevent mother-to-child HIV transmission. The Skin-
ner et al. study evaluated 265 women from the OCTANE
trial who at baseline had a median age of 37 years, med-
ian CD4 of 121 cells/ll and HIV RNA of 5.2 log10 cop-
ies/ml.
Walker et al. [18] assessed the effect of CTX on sur-
vival, WHO stage, malaria, CD4 count, body mass index
(BMI) and haematological indices in HIV-infected
patients with CD4 count <200 cells/ll initiating ART in
Uganda and Zimbabwe in the Development of Antiretro-
viral Therapy (DART) trial for Africa which compared
ART monitoring strategies in resource limited settings.
The trial enrolled 3179 participants; the analysis of
malaria incidence was restricted to 2222 participants in
Uganda. At enrolment into the DART trial, median CD4
count was 83 cells/ll.
Effect of CTX on malaria in patients on ART
Two of the six studies evaluated the effect of CTX on
malaria in HIV-positive participants on ART as their
main study objective. The other four studies had different
objectives, but the data allowed assessment of the effect
of CTX on malaria.
The six studies used different comparison groups: CTX
and ART vs. ART alone (4 studies); CTX and ART vs.
HIV negative (1 study); CTX only vs. HIV negative (1
study); CTX only vs. HIV positive not on treatment (1
study); CTX and ART vs. HIV positive not on treatment
(1 study); CTX, ART and ITNs vs. HIV positive not on
treatment (1 study).
All four studies that examined the occurrence of
malaria in HIV-positive persons on CTX and ART com-
pared with those on ART alone found a beneficial effect
of CTX. Bwakura-Dangarembizi et al. [34] found that
children and adolescents who discontinued CTX had a
higher incidence of malaria (HR 2.21, 95% CI = 1.50–
3.25 P < 0.001) compared to those who continued CTX
prophylaxis. Campbell et al. [35] also found strong evi-
dence of a higher malaria incidence in patients on ART
4 © 2015 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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who discontinued CTX compared to those who contin-
ued CTX prophylaxis (IRR 33; 95% CI = 9–275,
P < 0.001). Walker et al. [18] found strong evidence of a
reduction in the number of clinical malaria episodes
among patients on ART and CTX compared to those on
ART alone (OR = 0.74, 95% CI = 0.63–0.88,
P < 0.001); however, the reduction in the risk of para-
sitaemia was not statistically significant (OR 0.85; 95%
CI = 0.65–1.11, P = 0.23). Skinner et al. [36] found
weak evidence of decrease in detectable parasitaemia in
patients who were on CTX and ART compared to those
who were on ART alone (3.6% vs. 2.4%; P = 0.14).
Gasasira et al. [12] found a 76% (95% CI = 63–84%)
reduction in malaria incidence in children on CTX and
ART, and a similar 83% (95% CI = 74–89%) reduction
in children on CTX only, when both were compared with
HIV-negative children not on CTX.
Mermin et al. [19] found that CTX alone was associ-
ated with 76% reduction in malaria incidence
(RR = 0.24, 95% CI = 0.15–0.38; P < 0.001), and CTX
and ART reduced malaria incidence by 92% (RR = 0.08,
95% CI = 0.04–0.17; P < 0.001), when compared with
HIV-positive participants not on CTX or ART. In their
sequential comparisons of the additive effects of the inter-
ventions in each phase of the study, they found that add-
ing ART to CTX was associated with a 64%
(RR = 0.36, 95% CI = 0.18–0.74; P = 0.006) reduction
in malaria incidence compared to CTX alone.
Four studies reported parasite density. Bwakura-Dan-
garembizi et al. [34] found parasite density to be higher
in patients on ART who stopped CTX compared with
those who continued CTX (median parasite density per
200 white cells = 221/ll vs. 153/ll, P = 0.004). Campbell
et al. [35] found that 70% of the 55 malaria episodes in
patients on ART who stopped CTX had parasite densities
>1250/ll compared with 100% of the two episodes in
patients who continued CTX. Gasasira et al. [12] found
that geometric mean parasite density was lower for HIV-
infected children who were also on CTX (6462/ll) com-
pared to HIV-uninfected children (11 270/ll), although
the difference was not statistically significant (P = 0.40).
Mermin et al. [19] evaluated the cumulative and additive
effects of CTX, ART and ITNs on malaria parasitaemia
>1250/ll; their conclusions were similar to those when
malaria was defined as fever with a positive blood slide
(as described above).
Risk of bias and confounding
All studies reviewed were of good quality but subject to
sources of bias (Table 2). Three studies reported adher-
ence to CTX (Bwakura-Dangarembizi, Campbell and
Gasasira et al.), and 3 (Bwakura. Mermin and Walker
et al.) reported adherence to ART. Only the Bwakura
et al. study reported both CTX and ART adherence.
Campbell et al. and Bwakura-Dangarembizi et al. were
the only studies randomised by CTX use; however, these
studies were not blinded. Most of the studies used clinical
and/or laboratory based methods to diagnose malaria;
Walker et al. also used clinical diagnosis alone.
Multivariate analysis to control for potential confound-
ers was not used by Skinner et al. due to the small number
of malaria cases. Only the Mermin, Bwakura-Dan-
garembizi and Walker studies controlled for the potential
confounding effect of CD4 count at baseline. No study
explored the potential confounding effect of socio-eco-
nomic status. The Walker study was the only study to
control for potential time-dependent confounders such as
current CD4 count, haemoglobin and BMI levels.
Discussion
Most studies in this review were conducted after 2005,
when most developing countries had started to roll out
ART to patients, of whom most were on CTX. The
search was performed using terms for malaria, HIV and
CTX, without using the term for ART, to reduce the
chance of missing relevant papers. However, only six
studies were identified with data on the effect of CTX on
malaria in patients on ART.
Four of the six studies compared malaria occurrence in
patients on ART alone with that in patients on ART and
CTX, and all found a higher incidence of malaria in
patients on ART alone. This is expected given the anti-
malarial properties of CTX[38], even in areas where
malaria parasites have antifolate resistance[12]. The
strongest evidence for this beneficial effect was observed
in the Campbell (IRR = 32.5) and Bwakura-Dan-
garembizi (HR = 2.21) studies. The latter study was con-
ducted in children and adolescents and the former in
adults. With better immune memory to malaria in adults
[39], a smaller difference in malaria incidence between
those stopping CTX and those continuing CTX might be
expected in adults than in children, but the reverse was
observed. The Campbell study was stopped after just
4 months because of increased malaria incidence in the
discontinuation arm. As the authors point out, it is not
clear whether the increase in malaria after stopping CTX
may have been only temporary. It is possible that the lar-
ger beneficial effect of CTX on malaria in adults in this
study, compared with that in children and adolescents in
the Bwakura-Dangarembizi study, is because of the
shorter follow-up time (4 months vs. 2.1 years,
respectively).
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The other two studies showed strong evidence of a
decrease in episodes of clinical malaria (Walker et al.
OR = 0.74, 95% CI = 0.63–0.88; P < 0.001), and weak
evidence of a decrease in malaria prevalence (Skinner
et al. 3.6% vs. 2.4%, P = 0.14), in patients on ART and
CTX compared to patients on ART alone. One study
showed that HIV-infected children on CTX had 80%
(95% CI; 72–85%) lower malaria incidence than HIV-
negative children not on CTX.
Only the Bwakura-Dangarembizi and Campbell studies
were originally designed to look at the effect of CTX on
malaria in patients on ART. This may explain why most
studies did not report adherence to CTX and/or ART
and did not attempt to address potential bias and con-
founding related to malaria. Both the Bwakura-Dan-
garembizi and Campbell studies were randomised by
CTX use, but investigators and participants were not
blinded. These trials showed that patients stopping CTX
prophylaxis had a higher risk of malaria than those who
continue CTX. The Bwakura-Dangarembizi study
reported more hospitalisations in children stopping CTX
than in those who continued. The Campbell study
showed no significant difference in adult hospitalisation
rates or mortality between the trial arms, and none of the
four deaths recorded was related to malaria. Malaria in
this study was uncomplicated and the clinical relevance
of this malaria is therefore not clear.
Results of a trial ‘CTX Prophylaxis Discontinuation
Among ART-Treated Adults: A Randomized Non-Inferi-
ority Trial’ were presented at the Conference on Retrovi-
ruses and Opportunistic Infections in March 2014[40].
These results were not included in this synthesis because
some data relevant to the review were not provided and
the results are yet to be published in a peer-reviewed
journal. This trial was an open-label randomised con-
trolled trial comparing stopping vs. continuing CTX pro-
phylaxis among 500 HIV-infected adults in western
Kenya on ART >18 months and followed for a year. The
authors reported that patients stopping CTX had a 33.2
(95% CI = 4.5–241.0; P = 0.001) times higher malaria
incidence than those who continued CTX. They also
found that combined morbidity and mortality were
greater in the group stopping CTX (IRR 2.27; 95%
CI = 1.52–3.38, P < 0.001) but that this result was dri-
ven by malaria morbidity.
Publication of the full results of this trial is awaited
but like the Campbell study, this trial was not blinded
and therefore susceptible to reporting bias. However, the
results suggest that the higher incidence of malaria
seen in patients stopping CTX in the Campbell study
may be maintained even when patients are followed for
longer.
It is clear from this review that patients who are stable
on ART and stop taking CTX experience malaria epi-
sodes more frequently but a number of questions remain
unanswered:
• Given that none of the studies was blinded, how
much does reporting bias contribute to the observed
increased risk of malaria in patients who stop CTX
compared to that in those who continue?
• What is the clinical significance of malaria occurring
in HIV-infected adults on ART who do not take
CTX prophylaxis?
• Do patients who stop CTX have a higher incidence
of malaria than would be observed in HIV-unin-
fected people?
• How does CTX compare with other antimalaria pro-
phylactic drugs such as chloroquine (which may
imply a lower pill burden)?
• Does the background ecological exposure to malaria
have an effect on the relationship between malaria
and CTX?
• Is CTX prophylaxis still beneficial in patients recently
diagnosed with HIV who start ART early, that is with
high CD4 counts, for example 500 cells/ll?
Two ongoing randomised controlled trials, one in
Uganda (ISRCTN44723643) and one in Malawi
(NCT01650558), will help answer some of these ques-
tions. These studies investigate the effect of CTX on
malaria incidence in HIV-infected patients on ART. The
Ugandan trial is double-blind and placebo-controlled,
and compares continued CTX prophylaxis with stopping
CTX. The Malawian trial compares continued CTX with
stopping CTX, but is not placebo-controlled; instead
weekly chloroquine (CQ) prophylaxis is substituted for
CTX. Results are expected in 2015.
Conclusion
Few studies have investigated the effect of CTX on
malaria in patients on ART; these studies show a trend
towards a beneficial effect of CTX on malaria. Only 2 of
the reviewed studies were randomised and they were the
only ones specifically designed to investigate this associa-
tion. Most of the reviewed studies were subject to bias
and confounding, and the clinical relevance of malaria
experienced by patients stable on ART who are not on
CTX prophylaxis is unclear.
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